Cargando…
Infliximab-Associated Psoriasiform Dermatitis: Case Report and Review of a Seemingly Paradoxical Inflammatory Response
Background: Tumor necrosis factor-α (TNF-α) inhibitors, such as infliximab, adalimumab, and certolizumab pegol are effective agents in the treatment of inflammatory bowel disease. Some individuals undergoing anti-TNF-α therapy for Crohn’s disease or ulcerative colitis develop psoriasiform lesions. T...
Autores principales: | Loh, Tiffany Y, Cohen, Philip R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059146/ https://www.ncbi.nlm.nih.gov/pubmed/27738572 http://dx.doi.org/10.7759/cureus.773 |
Ejemplares similares
-
Infliximab-Associated Xanthogranulomatous Pyelonephritis: A Rare Complication
por: Alzanbagi, Adnan, et al.
Publicado: (2022) -
Infliximab treatment–induced paradoxical psoriasiform reaction in patient with psoriasis vulgaris showing positive lymphocyte transportation test reaction
por: Ishii-Osai, Yasue, et al.
Publicado: (2015) -
Infliximab-Induced Non-specific Interstitial Pneumonitis in a Patient With Ulcerative Colitis (UC)
por: Nasir, Syed Alishan, et al.
Publicado: (2022) -
Psoriasiform Eruption Secondary to PI3K-delta Inhibitor: Expanding the Spectrum of Psoriasiform Paradoxical Reactions?
por: PESQUÉ, David, et al.
Publicado: (2021) -
Psoriasiform Dermatitis in a COVID-19 Patient
por: Wu, Marlyn, et al.
Publicado: (2022)